Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda Named One of the Best Workplaces by Fortune Magazine and Great Place to Work

Business Wire October 12, 2016

Acorda Announces Departure of Michael Rogers

Business Wire October 4, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  September 29, 2016

Monday Market Wrap: Stocks Fall Nearly 1% To Start Week

Benzinga.com  September 26, 2016

Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade

Benzinga.com  September 26, 2016

Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News

Benzinga.com  September 26, 2016

Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss

Benzinga.com  September 26, 2016

Acorda Launches “The Many Faces of OFF” Facebook Page to Support Parkinson’s Community

Business Wire September 15, 2016

Acorda Provides Financial and Pipeline Update for Second Quarter 2016

Business Wire July 28, 2016

Acorda to Host Conference Call to Discuss Second Quarter 2016 on July 28, 2016

Business Wire July 7, 2016

Acorda Appoints Burkhard Blank, M.D., as Chief Medical Officer (CMO)

Business Wire July 1, 2016

Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective

Business Wire June 13, 2016

Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics

PR Newswire June 9, 2016

Boston Medical Center Avoids 8,500 tons of Carbon Annually by Leveraging Veolia's "Green Steam" Energy

PR Newswire June 9, 2016

Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society

Business Wire June 9, 2016

Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference

Business Wire May 31, 2016

Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters

Business Wire May 20, 2016

Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market

Business Wire May 18, 2016

Acorda Therapeutics Named One of the Best Places to Work for in New York

Business Wire May 4, 2016

Final Results of the Subsequent Offer Period of Acorda Therapeutics' Tender Offer for All of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp.

Business Wire May 2, 2016